Krystal Biotech

Illustration connected puzzle pieces with the acronym MA
Special Reports

10 top M&A targets in biotech for 2023

After a slow 2022, will we see a return to form for biopharma M&A? And, if so, which biotechs does Big Pharma have in its sight? Here are our predictions.
Green traffic light

Krystal Biotech eyes phase 3 for rare skin disease gene therapy

Jun 24, 2019 11:13am
Novartis

Novartis farms out rare disease drug to LifeMax Labs

Aug 27, 2018 10:30am
Nasdaq

Krystal files for IPO to move gene therapies into clinic

Aug 22, 2017 10:23am